Modification of WR-2721 toxicity and radioprotection by an inhibitor of alkaline phosphatase.
We used levamisole, an inhibitor of alkaline phosphatase, to study the role of that enzyme in mediating the metabolic activation, toxicity, and radioprotection of WR-2721 in intact mice. We found the toxicity of WR-2721 was slightly decreased by prior subcutaneous (SQ) injection of 40 mg/kg of levamisole. In studying the effect of levamisole on WR-2721 radioprotection, we found that intraperitoneal (i.p.) injection of levamisole had little or no effect on radioprotection of the gastrointestinal and the hematopoietic systems. Even this small reduction of protection was due in part to the toxicity of levamisole as demonstrated when levamisole was injected following, rather than before, WR-2721-radiation treatment. To determine whether levamisole inhibited the activation (i.e., dephosphorylation) of WR-2721 to WR-1065, we assayed WR-1065 in the jejunum using an HPLC electrochemical assay. SQ injection of 75 mg/kg levamisole 10 min prior to WR-2721 reduced the WR-1065 observed 10 min after WR-2721 administration by 37%. In conclusion, levamisole appears to be too toxic and non-specific to be useful in studying and regulating the metabolism, toxicity and radioprotection of WR-2721.
D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors*; D004999:Amifostine / Q000378:metabolism / Q000633:toxicity*; D000818:Animals; D001711:Biotransformation; D007978:Levamisole / Q000494:pharmacology; D008624:Mercaptoethylamines / Q000378:metabolism; D051379:Mice; D009946:Organothiophosphorus Compounds / Q000633:toxicity*; D011837:Radiation-Protective Agents / Q000378:metabolism / Q000633:toxicity*
D008624:Mercaptoethylamines; D009946:Organothiophosphorus Compounds; D011837:Radiation-Protective Agents; C020174:N-(2-mercaptoethyl)-1,3-diaminopropane; D007978:Levamisole; D000469:Alkaline Phosphatase; D004999:Amifostine